Miromatrix is working toward eliminating the organ transplant waiting list by bioengineering transplantable organs, including liver, kidney and heart.
Location: United States, Minnesota, Eden Prairie
Employees: 51-200
Total raised: $2M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Gravity Fu... | gravityfun... |
| - | DaVita Ven... | davitavent... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.10.2019 | Grant | $2M | - |
Mentions in press and media 5
| Date | Title | Description |
| 21.10.2019 | Miromatrix Awarded $2M in Grant From NIH for Bioengineered Liver | Local biotech company Miromatrix Medical has received a $1.97 million grant from the National Institute of Diabetes and Digestive Kidney Diseases to continue the development of its bioengineered liver. There are currently more than 100,000 ... |
| 11.08.2014 | Miromatrix raising $20M for lab-grown organ scaffolding tech | Miromatrix gives scientists a kind of framework to build organs. It uses cells to build up an outline, so they can fill in the gaps, or color within the lines, if you will, with a palette of cells. To clarify: The company removes cells from... |
| 24.02.2012 | Regenerative medicine firm raises $2M on path to revolutionize healthcare | The two-year-old company, which counts former Republican Gov. Tim Pawlenty as a board member, has also formally launched a website. It was in Pawlenty’s administration that Miromatrix received two nondilutive loans totaling $500,000. Needle... |
| - | Miromatrix raising $20M for lab-grown organ scaffolding tech | Scientists are on the lookout for the best lab-grown organ , with 3-D cellular scaffolding emerging as the technology to beat. Minnesota-based Miromatrix Medical falls into this category, and though it’s been a while since we’ve heard somet... |
| - | Regenerative medicine firm raises $2M on path to revolutionize healthcare | UPDATED AND CORRECTED Regenerative medicine firm Miromatrix Medical, which one day aims to grow human organs, has raised $2.05 million, according to a January letter to shareholders from CEO Robert Cohen. The two-year-old company, which cou... |